Cholangitis in patients with atrial fibrillation
A retrospective cohort study in Taiwan

Wei-Syun Hu, MD, PhD	a,b,∗, Cheng-Li Lin, MS	c

Abstract
The purpose of this study is to investigate whether atrial fibrillation (AF) and cholangitis is associated.
This is a propensity-matched retrospective cohort report from the Taiwan National Health Insurance Research Database. We included patients who had AF but didn’t have cholangitis, and matched controls between January 1, 2000 and December 31, 2012. The AF cohort comprised 114,572 patients and the comparison cohort comprised 114,572 subjects. All participants were followed up until developing cholangitis, death, or December 31, 2013, whichever came first. The cox model was used to calculate the adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for comparing the risk of cholangitis in the AF cohort and non-AF cohort.
The incidence of cholangitis was higher in patients with AF than in those without AF [4.2 and 2.54 per 1000 person–years; adjusted HR (95%CI), 1.92[1.54, 2.41]]. Comparing to subjects without AF, patients with AF had higher risk of cholangitis in the subgroup of ≥65 years (adjusted HR = 1.76, 95%CI = 1.40–2.21), female (adjusted HR = 2.51, 95%CI = 1.74–3.63), male (adjusted HR = 1.60, 95%CI = 1.19–2.14), without comorbidities (adjusted HR = 1.79, 95%CI = 1.23–2.61), and with comorbidities (adjusted HR = 1.85, 95%CI = 1.73–1.99).
AF is associated with a higher incidence of cholangitis. The need of further investigations is mandatory because of the inherent limitations of observational study.
Keywords: atrial fibrillation, cholangitis, cohort

1. Introduction
Impact of atrial fibrillation (AF) on lifespan is well established, mostly through the effect of cardiovascular disease.[1–3] Indeed, research on AF is increasingly growing and remains a hot issue. However, compared to the AF-associated cardiovascular effect, the impact of AF on noncardiovascular disorders has gain few attentions.[4–8] Cholangitis, although it was once thought to be a localized gastrointestinal disorder, has been reported to be associated with cardiovascular disease and diabetes mellitus.[9–11] It would appear interesting and novel to exam whether the association between AF and cholangitis exists. Hence, with a huge population data acquired from the Taiwan National Health Insurance Research Database and consisted of 114,572 AF patients and 114,572 controls, we conducted the observational cohort secondary data analysis study to explore this issue that are currently not available in medical literature.

2. Methods
2.1. Data source
We used inpatients files of the National Health Insurance Research Database which built by Taiwan National Health Research Institute.[12] This study has been approved by the Research Ethics Committee at China Medical University Hospital (CMUH104-REC2-115-AR-4). International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes were used in this study.

2.2. Sample participants
We designed a national population-based study to analyze all inpatient patients, and we survey the AF (ICD-9-CM code 427.31) patients whether they had higher risk of cholangitis. Our study cohort included patients with a diagnosis of AF for the first time between January 1, 2000 and December 31, 2012. Each patient’s date of first diagnosis of AF from the hospital was considered as the index date. Those who had a diagnosis of
cholangitis before index date, a diagnosis of heart failure before endpoint, and incomplete age or sex information were excluded. The comparison cohort were selected subjects without a diagnosis of AF during the same study period. Selected comparison individuals with a history of cholangitis before the index date, with incomplete age or sex information were excluded. The risk rates of cholangitis in the two cohort were evaluate and compared, and two cohorts were propensity-score matched at a ratio of 1:1 based on the baseline characteristics of the patients including age, sex, AF diagnosis year, and comorbidities of chronic kidney disease, end stage renal disease, gallbladder stone disease, hyperlipidemia, obesity, diabetes, alcoholism, chronic hepatitis B virus infection, chronic hepatitis C virus infection, hypertension, coronary artery disease, chronic obstructive pulmonary disease, peripheral arterial occlusive disease, gout, stroke, pancreatitis, rheumatic disease, cancer, and inflammatory bowel disease. A total of 114,572 AF patients and 114,572 controls without AF were enrolled in our study. Mortality rates were considered when comparing risk rates to eliminate the influence of death on the calculated risk of cholangitis. All participants were followed up until developing cholangitis, death, or December 31, 2013, whichever came first (Fig. 1).

2.3. Outcome and comorbidity

The major outcome in this study was cholangitis (ICD-9-CM code 576.1). Associated comorbidities were also considered as potential confounding factors in this study, such as chronic kidney disease, end stage renal disease, gallbladder stone disease, hyperlipidemia, obesity, diabetes mellitus, alcoholism, chronic hepatitis B virus infection, chronic hepatitis C virus infection, hypertension, coronary artery disease, chronic obstructive pulmonary disease, peripheral arterial occlusive disease, gout, stroke, pancreatitis, rheumatic disease, cancer, and inflammatory bowel disease.

2.4. Statistical analysis

For each AF patient, a matched control was assigned using the propensity score matching technique to account for baseline differences between AF and non-AF subjects. The propensity score was assigned based on the probability that an individual would be a case of AF and estimated by a multivariable logistic

---

**Figure 1.** The flow diagram of this study.
regression model adjusting for observed covariates. All the confounders such as age, gender and comorbidities were included in the propensity-score model. Demographic characteristics and the prevalence of comorbidities were compared by standardized mean difference in which values \(< 0.10\) indicated a negligible difference between the two cohorts. We estimated the cumulative incidences of cholangitis for the AF and comparison cohorts with Kaplan–Meier method, and we examined the difference between the two curves by log-rank test. Multivariate models were simultaneously adjusted for age, gender, and comorbidities. The cox model was used to calculate the adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for comparing the risk of cholangitis in the AF cohort relative to the non-AF cohort. The Fine and Gray model, which extended the univariate and multivariate cox proportional-hazard regression model, were used to estimate the subhazard ratios of cholangitis by considering death as a competing risk. We used SAS software (version 9.4 for Windows; SAS Institute, Cary, NC) for all statistical analyses and Kaplan-Meier survival curves plot. A 2-sided \(P\)-value less than .05 was considered statistically significant.

### 3. Results

After propensity-score matching, our study cohort consisted of 229,144 patients (93775 women and 135,369 men). The AF cohort comprised 114,572 patients and the comparison cohort comprised 114,572 subjects. The matched baseline characteristics and comorbidities of all participants are listed in Table 1. Among the study subjects, male gender and age \(\geq 65\) years were dominant. The matched pairs were similar with respect to all covariates, including age, sex, and all comorbidities (all standardized mean difference \(< 0.10\)).

Table 1: Demographic characteristics and comorbidities of patients with and without atrial fibrillation.

| Atrial fibrillation | Yes \((N=114,572)\) | No \((N=114,572)\) | Standardized mean differences | \(P\)-value |
|---------------------|----------------------|----------------------|-------------------------------|-------------|
| Age, yr             |                      |                      |                               |             |
| \(\leq 64\)         | 28,582 25.0          | 26,971 23.5          | 0.03                          |             |
| \(\geq 65\)         | 85,990 75.1          | 87,601 76.5          | 0.03                          |             |
| Mean (SD)*          | 72.3 13.2            | 72.3 12.8            | 0.000                         | .82         |
| Gender              |                      |                      |                               |             |
| Female              | 47,072 41.1          | 46,703 40.8          | 0.01                          | .01         |
| Male                | 67,500 58.9          | 67,869 59.2          | 0.01                          | .01         |
| Comorbidity         |                      |                      |                               |             |
| CKD                 | 6808 5.94            | 6949 6.07            | 0.01                          | .22         |
| ESRD                | 3857 3.37            | 3926 3.43            | 0.003                         | .43         |
| GB stone disease    | 9491 8.28            | 9722 8.49            | 0.01                          | .08         |
| Hyperlipidemia      | 18,681 16.3          | 19,256 16.8          | 0.01                          | .001        |
| Obesity             | 94 0.08              | 104 0.09             | 0.003                         | .48         |
| Diabetes            | 35,675 31.1          | 36,225 31.6          | 0.01                          | .01         |
| Alcoholism          | 1983 1.73            | 1978 1.73            | 0.000                         | .94         |
| Chronic HBV infection | 2894 2.53           | 2977 2.60            | 0.01                          | .27         |
| Chronic HCV infection | 3096 2.70           | 3151 2.75            | 0.003                         | .48         |
| Hypertension        | 76,706 67.0          | 77,242 67.4          | 0.01                          | .02         |
| CAD                 | 44,114 38.5          | 44,643 39.0          | 0.01                          | .02         |
| COPD                | 26,774 23.4          | 26,944 23.5          | 0.004                         | .40         |
| PAOD                | 7026 6.13            | 7317 6.39            | 0.01                          | .01         |
| Gout                | 9883 8.63            | 10,074 8.79          | 0.01                          | .16         |
| Stroke              | 48,499 43.2          | 50,313 43.9          | 0.01                          | .001        |
| Pancreatitis        | 2631 2.30            | 2647 2.31            | 0.001                         | .82         |
| Rheumatic disease   | 1397 1.22            | 1437 1.25            | 0.003                         | .45         |
| Cancer              | 18,356 16.0          | 18,675 16.3          | 0.01                          | .07         |
| Inflammatory bowel disease | 327 0.29       | 333 0.29            | 0.001                         | .82         |

Chi-square test.

* t test.

CAD = coronary artery disease, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, ESRD = end stage renal disease, GB = gallbladder, HBV = hepatitis B virus, HCV = hepatitis C virus, PAOD = peripheral artery occlusive disease, SD = standard deviation.

Table 2 shows that the incidence and hazard ratio of cholangitis in AF patients compared to those without AF. The incidence of cholangitis was higher in patients with AF than in those without AF [4.2 and 2.54 per 1000 person–years; adjusted HR (95%CI), 1.92(1.54, 2.41)]. After controlling for potential confounding factors, comparing to subjects without AF, patients with AF had a higher risk of cholangitis in the subgroup of age \(\geq 65\) years (adjusted HR = 1.76, 95%CI=1.40–2.11), female (adjusted HR = 2.51, 95%CI=1.74–3.63), male (adjusted HR = 1.60, 95%CI=1.19–2.14), without comorbidities (adjusted HR = 1.79, 95%CI=1.23–2.61), and with comorbidities (adjusted HR = 1.85, 95%CI=1.73–1.99).

The competing risk regression model which considered the competing risk of death is shown in Table 3. After adjustment for confounding factors in the competing risk regression model, the risk of cholangitis remained significantly increased in the AF cohort (adjusted subhazard ratio = 1.43, 95%CI 1.15–1.76, \(P < .001\)).
Figure 2 shows the cumulative incidence curves of cholangitis for groups with and without AF. From the first year of follow-up to the end of the study period, the incidence of cholangitis events in the AF cohort was higher than in the comparison cohort.

4. Discussion

In this study, we found a significant increase in cholangitis in the AF cohort as compared to the controls. Interestingly, this association was much more profound in the subgroup of ≥65 years, women and with comorbid medical illness.

Strengths of the manuscript include: evaluation of a clinically important issue; large cohort of patients extracted from the impressive database; and appropriate statistical techniques for analysis, especially matching for age, sex and comorbidities in both groups as per Table 1.

It is well established that AF is associated with stroke, heart failure, and mortality.\textsuperscript{[1–3]} Some might be bewildered on which bases would the authors come up with the hypothesis that AF would constitute a direct or indirect risk for developing a cholangitis since AF could lead to thromboembolic events or cause a heart failure over the years but both are difficult to bring in relation to a cholangitis. Known predisposing risk factors for a cholangitis being rather hepatic or bile duct diseases, gallstones etc. As such, some might argue that it seems that this is rather a coincidental byproduct of a statistical exercise. Indeed, the association between AF and gastrointestinal complications are limited.\textsuperscript{[13,14]} However, it has been adequately shown in this

### Table 2
Comparison of incidence and hazard ratio of cholangitis stratified by age, gender, and comorbidity between patients with and without AF.

| Variable | Event | PY  | Rate\(^1\) | Event | PY  | Rate\(^1\) | Crude HR (95%CI) | Adjusted HR\(^1\) (95%CI) |
|----------|-------|-----|------------|-------|-----|------------|------------------|--------------------------|
| All      | 1799  | 428,376 | 4.2       | 1533  | 604,385 | 2.54      | 1.64 (1.53, 1.76)*** | 1.92 (1.54, 2.41)*** |
| Age, y<\(\leq64\) | 250   | 156,639 | 1.60      | 161   | 171,043 | 0.94      | 1.69 (1.39, 2.06)*** | 2.27 (0.66, 7.84) |
|         | 1549  | 271,737 | 5.70      | 1372  | 433,342 | 3.17      | 1.80 (1.67, 1.94)*** | 1.76 (1.40, 2.21)*** |
| Gender Female | 704   | 174,788 | 4.03      | 594   | 248,439 | 2.39      | 1.66 (1.49, 1.86)*** | 2.51 (1.74, 3.63)*** |
| Male     | 1095  | 253,588 | 4.32      | 939   | 355,945 | 2.64      | 1.63 (1.49, 1.76)*** | 1.60 (1.19, 2.14)*** |
| Comorbidity†| No    | 54    | 42,007    | 1.29  | 63   | 54,831    | 1.15      | 1.10 (0.76, 1.58)      | 1.79 (1.23, 2.61)*** |
|         | Yes   | 1745  | 386,369   | 4.52  | 1470 | 549,554   | 2.67      | 1.68 (1.57, 1.80)†††   | 1.85 (1.73, 1.99)*** |

AF = atrial fibrillation, CAD = coronary artery disease, CI = confidence intervals, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, ESRD = end stage renal disease, GB = gallbladder, HBV = hepatitis B virus, HCV = hepatitis C virus, HR = hazard ratio, PAOD = peripheral artery occlusive disease, PY = person–years.

† Rate, incidence rate per 1000 person-years; Crude HR, relative hazard ratio.

†† Comorbidity: Patients with any one of the comorbidities were classed as the comorbidity group: CKD, ESRD, GB stone disease, hyperlipidemia, obesity, diabetes, alcoholism, chronic HBV infection, chronic HCV infection, hypertension, CAD, COPD, PAOD, gout, stroke, pancreatitis, rheumatic disease, cancer, and inflammatory bowel disease.

‡ Model was mutually adjusted for age, sex, and comorbidities of CKD, ESRD, GB stone disease, hyperlipidemia, obesity, diabetes, alcoholism, chronic HBV infection, chronic HCV infection, hypertension, CAD, COPD, PAOD, gout, stroke, pancreatitis, rheumatic disease, cancer, and inflammatory bowel disease.

\(\ast\ast\ast\) \(P<.001\).

### Table 3
Incidence and subhazard ratio (SHR) of cholangitis in propensity score (PS)-matched cohorts, using the univariable and multivariable competing-risks regression models.

| Outcome | Without atrial fibrillation | With atrial fibrillation |
|---------|-----------------------------|--------------------------|
| Crude SHR (95%CI) | 1.22 (1.14, 1.31)*** | 1.43 (1.15, 1.76)*** |
| Adjusted SHR\(^1\) (95%CI) | 1 (Reference) | 1 (Reference) |

Crude SHR, relative subhazard ratio.

CAD = coronary artery disease, CI = confidence intervals, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, ESRD = end stage renal disease, GB = gallbladder, HBV = hepatitis B virus, HCV = hepatitis C virus, PAOD = peripheral artery occlusive disease.

\(^1\) Model was mutually adjusted for age, sex, and comorbidities of CKD, ESRD, GB stone disease, hyperlipidemia, obesity, diabetes, alcoholism, chronic HBV infection, chronic HCV infection, hypertension, CAD, COPD, PAOD, gout, stroke, pancreatitis, rheumatic disease, cancer, and inflammatory bowel disease.

\(\ast\ast\ast\) \(P<.001\).
analysis that associations between AF and cholangitis differ according to age, gender, and comorbidity status. While the result is statistically significant, and might be an interesting topic which would add to the evidence in this field. It remains an association and the firm conclusion regarding any insight into causality should be interpreted very carefully. Hence, further large scale prospective studies are highly recommended.

Since AF usually occurs in patients who are older and sicker,[15,16] the concept that these factors that contribute to AF causation also make cholangitis more likely. In addition, we found that women with AF are more frequent with incident cholangitis than the comparisons. The underlying expiations for this observation is difficult to conclude due to the nature of the association investigation. Whether it is just an incident finding or it reflects a novel association remained to be determined.

4.1. Limitations

Limitations of the study include: lack of standard robust techniques to detect AF; ascertainment bias, with the likelihood that those with AF have more intense follow up and increasing the probability of diagnosing a cholangitis; retrospective analysis; potential for confounding variables which were not measured and lack of medications in the analysis; use of administrative data for diagnosis of AF, comorbidities, and endpoints; and cause and effect is unclear due to the nature of association studies.

5. Conclusion

A higher incidence of cholangitis among AF patients is found.

Author contributions

Conceptualization: Wei-Syun Hu.
Data curation: Wei-Syun Hu.
Formal analysis: Wei-Syun Hu, Cheng-Li Lin.
Investigation: Wei-Syun Hu.
Methodology: Wei-Syun Hu, Cheng-Li Lin.
Project administration: Wei-Syun Hu.
Resources: Wei-Syun Hu.
Software: Wei-Syun Hu, Cheng-Li Lin.
Supervision: Wei-Syun Hu.
Validation: Wei-Syun Hu.
Visualization: Wei-Syun Hu.

Writing – original draft: Wei-Syun Hu, Cheng-Li Lin.
Writing – review & editing: Wei-Syun Hu, Cheng-Li Lin.

References

[1] Chugh SS, Roth GA, Gillum RF, Mensah GA. Global burden of atrial fibrillation in developed and developing nations. Glob Heart 2014;9:113–9.
[2] Lau DH, Nbett S, Kalman JM, Sanders P. Modifiable risk factors and atrial fibrillation. Circulation 2017;136:583–96.
[3] Ganesan AN, Chew DP, Hartshorne T, et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. Eur Heart J 2016;37:1591–602.
[4] Bewelem WCS, Halperin JL, Adabag S, et al. Extracranial systemic embolic events in patients with nonvalvular atrial fibrillation: incidence, risk factors, and outcomes. Circulation 2013;129:796–803.
[5] Hald EM, Rinde LB, Laschen ML, et al. Atrial fibrillation and cause-specific risks of pulmonary embolism and ischemic stroke. J Am Heart Assoc 2018;7:3.
[6] Silva RMFLD, Miranda CM, Liu T, Tse G, Roever L. Atrial fibrillation and risk of dementia: epidemiology, mechanisms, and effect of anticoagulation. Front Neuropsi 2019;1:13.
[7] Hu WS, Lin CL. Suicide attempt in patients with atrial fibrillation – a nationwide cohort study. Prog Neuropsychopharmacol Biol Psychiatry 2019;92:470–5.
[8] Conen D, Wong JA, Sandhu RK, et al. Risk of malignant cancer among women with new-onset atrial fibrillation. JAMA Cardiol 2018;3:389–96.
[9] Suraweera D, Fanous C, Jimenez M, Tong MJ, Saab S. Risk of cardiovascular events in patients with primary biliary cholangitis – systematic review. J Clin Transl Hepatol 2018;6:119–26.
[10] Ludvigsson JF, Bergquist A, Montgomery SM, Rahmanyar S. Risk of diabetes and cardiovascular disease in patients with primary sclerosing cholangitis. J Hepatol 2014;60:802–8.
[11] Bian S, Chen H, Wang L, et al. Cardiac involvement in patients with primary biliary cholangitis: a 14-year longitudinal survey-based study. PLoS One 2018;13:e0194397.
[12] Hu WS, Lin CL. The predictive role of CHA2DS2-VASc score between venous thromboembolism and ischemic stroke: a large-scale cohort study. J Hypertens 2018;36:628–33.
[13] Hu WS, Lin CL. CHA2DS2-VASc score in the prediction of ischemic bowel disease among patients with atrial fibrillation: insights from a nationwide cohort. Int J Cardiol 2017;235:56–60.
[14] Laliberté F, Moore Y, Dea K, et al. Gastrointestinal comorbidities associated with atrial fibrillation. Springerplus 2014;3:603.
[15] Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129:837–47.
[16] Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 2014;6:213–20.